

The logo for VENENUM Biodesign features the word "VENENUM" in a bold, sans-serif font above a stylized blue oval containing a chemical structure and the word "Biodesign" in a smaller font.

FOR IMMEDIATE RELEASE

Biotech Company Relocates to State of the Art Facility

Hamilton, NJ., Jan. 3, 2011 – *VENENUM Biodesign*, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease based targets or its partners' targets, announced today it's relocation to a brand new, state of the art facility in Hamilton, NJ in Mercer County.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. *VENENUM BioDesign*, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley", the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state of the art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign compound Collection which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed Venenum Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and *in vitro* assay and *in vivo* model development. *VENENUM BioDesign's* new facility has been engineered to specifically accommodate their well published and experienced Target Biology department which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit- to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "our intention is to use our drug discovery capabilities to develop our own novel targets into therapeutic products as well as to provide access of our core capabilities to other companies and research institutions".

To find out more, please visit www.venenumbiodesign.com.

Contact:

Maria Webb, Ph.D.

Chief Scientific Officer (CSO)

mwebb@venenumbiodesign.com

609.570.1048

www.venenumbiodesign.com

#